Country: Canada
Language: English
Source: Health Canada
FLUTICASONE PROPIONATE
GLAXOSMITHKLINE INC
R03BA05
FLUTICASONE
50MCG
POWDER
FLUTICASONE PROPIONATE 50MCG
INHALATION
60 DOSES
Prescription
ADRENALS
Active ingredient group (AIG) number: 0124685001; AHFS:
CANCELLED POST MARKET
2015-10-09
_2014-07-29/131-pristine-english-Flovent.doc _ _ _ _ _ _Page 1 of 49_ PRODUCT MONOGRAPH PR FLOVENT ® HFA fluticasone propionate inhalation aerosol 50, 125, and 250 mcg/metered dose PR FLOVENT ® DISKUS ® fluticasone propionate powder for inhalation 50, 100, 250, and 500 mcg/blister Corticosteroid for Oral Inhalation GlaxoSmithKline Inc. 7333 Mississauga Road Mississauga, Ontario L5N 6L4 www.gsk.ca Date of Revision: July 29, 2014 Submission Control No: 174022 _©_ _2014. GlaxoSmithKline Inc. All rights reserved. _ _®_ _FLOVENT, DISKUS and BABYHALER are registered trademarks, used under license by GlaxoSmithKline Inc. _ _®_ _AEROCHAMBER PLUS is a registered trademark of Trudell Medical International _ _2014-07-29/131-pristine-english-Flovent.doc _ _ _ _ _ _Page 2 of 49_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ....................................................................................................9 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION ..............................................................................14 OVERDOSAGE ................................................................................................................18 ACTION AND CLINICAL PHARMACOLOGY ............................................................18 STORAGE AND STABILITY ..........................................................................................19 SPECIAL HANDLING INSTRUCTI Read the complete document